Myriad Genetics (MYGN) Free Cash Flow (2009 - 2026)

Myriad Genetics has disclosed Free Cash Flow across 18 years of filings, most recently posting -$21.1 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 2.31% year-over-year to -$21.1 million; the TTM figure through Mar 2026 stood at -$13.3 million (up 44.58% YoY), while the FY2025 annual figure was -$13.8 million, up 50.18% from the prior year.
• Free Cash Flow declined to -$21.1 million in Q1 2026, from $5.9 million in the prior quarter.
• Over the last five years, Free Cash Flow for MYGN reached as high as $18.3 million in Q3 2025 and fell as low as -$111.3 million in Q4 2023.
• The 5-year median for Free Cash Flow is -$19.7 million (2023), against an average of -$22.8 million.
• Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 533.71% — and 2025, when it jumped 753.57%.
• A 5-year view of Free Cash Flow shows it stood at -$52.6 million in 2022, then tumbled by 111.6% to -$111.3 million in 2023, then jumped by 102.7% to $3.0 million in 2024, then surged by 96.67% to $5.9 million in 2025, then plunged by 457.63% to -$21.1 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$21.1 million, $5.9 million, and $18.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.